Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
According to Reuters, Cliffs Natural Resources Inc. ( CLF - Analyst Report ) and Anglo American Plc. are set to divest their Amapa iron ore operation in Brazil to a single entity. Ohio-based Cliffs stated that the value of Amapa will be adjusted to reflect the fair value of its investment. The companies did not disclose the value of the deal.
Cliffs holds a 30% stake in the Amapa mine while the rest is owned by Anglo American. Cliffs expects to incur a charge of around $380 million to $420 million related to the divestiture for the year ended December 31, 2012.
Cliffs, in November 2012, announced its decision to halt production at two of its U.S. iron ore operations, Northshore Mining in Minnesota and Empire Mine in Michigan. The company also announced that it will delay portions of its Bloom Lake Mine Phase II expansion in Quebec. The company took these steps to adjust its 2013 operating plans for its North American iron ore businesses to align with expected sales volumes.
Cliffs released its third-quarter 2012 results in October 2012. The company posted earnings of 59 cents per share in the quarter, down 85.8% from $4.15 reported in the year-ago quarter. Declining iron ore prices and higher costs led to the slump in earnings. Earnings from continuing operation came in at 61 cents a share in the quarter. By that measure, it largely missed the Zacks Consensus Estimate of $1.05.
Sales for the quarter came in at $1,544.9 million, down 26% from $2,089.1 million in the prior-year quarter, missing the Zacks Consensus Estimate of $1,742 million. The decline in revenues resulted from a 36% year-over-year drop in seaborne iron ore pricing and higher labor, mining and maintenance costs.
Cliffs, which competes with CONSOL Energy Inc. ( CNX - Analyst Report ) and Alpha Natural Resources, Inc. ( ANR - Snapshot Report ) , currently retains a short-term Zacks #5 Rank (Strong Sell). Currently, we have a long-term (more than 6 months) Underperform recommendation on the stock.
Read the full Analyst Report on CLF
Read the full Analyst Report on CNX
Read the full Snapshot Report on ANR